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Abstract We describe a series of 5 patients in whom the
application of consensus criteria for the diagnosis of chronic
lymphocytic leukemia (CLL) led to a revised diagnosis.
These patients had been recruited in a wider study describing
the occurrence of CLL in Kenya. This case series highlights
some of the pitfalls of making a diagnosis of CLL without
incorporating all criteria.

and the International Workshop on CLL (IWCLL) requires
the following [3,4]:

•
•
•

Duration: Persistent lymphocytosis ≥3 months;
Counts: Monoclonal B cell count ≥5 × 109/L when there
is lymphocytosis only;
Morphology: Consistent morphology as defined by the
French-American-British (FAB) classification [5];
Immunophenotype: The prototype is co-expression of CD5
and CD23 in monoclonal B cells with dim expression of
surface immunoglobulin (sIg) and absent/dim CD79b (or
CD22), and the absence of expression of FMC7. The scoring system described by Matutes et al. can help distinguish
CLL from other non-Hodgkin lymphomas (NHL) on the
basis of immunophenotype [6,7].
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Résumé Nous décrivons une série de cinq patients chez lesquels l’application des critères de consensus pour le diagnostic de la leucémie lymphoïde chronique (LLC) a conduit à
une révision du diagnostic. Ces patients ont été recrutés dans
une étude plus large décrivant la LLC au Kenya. Cette série
de cas met en lumière les pièges dans le diagnostic de la LLC
quand tous les critères n’y sont pas intégrés.

Small lymphocytic lymphoma (SLL) and CLL are different presentations of the same disease [4].

Mots clés Pièges · LLC · Diagnostic

Introduction
The laboratory diagnosis of lymphoma has evolved over the
years from being based on morphology alone to the inclusion of immunophenotyping and molecular data [1–3]. Specifically, the diagnosis of chronic lymphocytic leukemia
(CLL) according to the World Health Organization (WHO)

Materials and methods
Patients were recruited as part of a wider study describing
the occurrence of CLL in Kenya [8]. Morphological evaluation was by FAB criteria. Results of immunophenotyping
were interpreted based on the scoring system described by
Matutes et al. [6,7].

Results
Criteria: Duration and counts
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Case 1: Case of essential thrombocythemia
A 62-year-old man was referred to Aga Khan University
Hospital, Nairobi (AKUH,N) for bone marrow evaluation
with a new diagnosis of CLL. The basis for this diagnosis
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was uncertain as records were not accessible. However,
history was significant for erythromelalgia and persistent
thrombocytosis, and the patient had not received any therapy
for CLL. Physical examination was noteworthy for the presence of moderate splenomegaly. Interestingly, the patient did
not have lymphocytosis. Subsequent blood counts were also
negative for lymphocytosis. There was no evidence of reactive thrombocytosis and bone marrow evaluation done was
consistent with essential thrombocythemia (ET).
Criterion: Morphology
Case 2: Case of HCL
A 61-year-old man was seen at AKUH,N seeking a second
medical opinion. He had been on follow-up as a case of
CLL. Clinical history was remarkable for recurrent anemia,
thrombocytopenia, and non-response to chlorambucil therapy. Physical examination was notable for pallor and massive splenomegaly. Morphology was, however, inconsistent
with CLL as per the FAB criteria (Fig. 1). Immunophenotyping confirmed the suspected diagnosis of hairy cell leukemia
(HCL). The immunophenotype was CD5−, CD23 borderline, bright sIg expression with lambda restriction, CD11c/
CD22 co-expression with bright CD22 expression, FMC7
positive, and CD103+.
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cells were CD19 positive and lacked surface immunoglobulin expression. Further immunophenotyping confirmed the
diagnosis of acute lymphoblastic leukemia (ALL) and an
amended report was issued (Fig. 2).
Cases 4 and 5 were elderly male patients with sustained
lymphocytosis. However, morphological evaluation was not
conclusive due to the presence of cleaved cells and moderate
amounts of cytoplasm (Fig. 3). A diagnosis of a chronic
lymphoproliferative disorder (CLPD) was given and CLL/
SLL and follicular lymphoma were suggested as possibilities. The immunophenotype for both, however, scored 5/5
which is highly specific for CLL [6]. CD 10 was negative
for both.

Discussion
The incorporation of relevant criteria for diagnosis of various
hematological malignancies is not merely of academic

Criterion: Immunophenotype
Case 3–5: Cases of diagnostic uncertainty
Case 3 was a 50-year-old female patient who had initially
been diagnosed as CLL on morphological evaluation of a
bone marrow aspirate. However, on immunophenotyping
of a peripheral blood sample with leukocytosis, most cells
were weak CD45 positive and suspicious for blasts. The

Fig. 2 Peripheral blood smear for Case 3

Fig. 1 Peripheral blood smear for Case 2 showing hairy cells

Fig. 3 Representative field of peripheral smear findings in Cases
4 and 5
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interest. It results in appropriate classification, prognostication, and management of patients. The management principles of ALL, HLL, and ET differ from those of CLL/SLL
[4,9]. Altering the diagnosis for the patients described in this
series, therefore, optimized their management.
While sub-Saharan Africa is plagued by resource limitations [10], incorporation of requisite criteria is vital when
circumstances permit an optimal evaluation. However,
even in the absence of access to more specialized tests like
immunophenotyping, clinical correlation using simple criteria like the presence and persistence of lymphocytosis can go
a long way in distinguishing transient from clonal causes of
lymphocytosis. Building expertise in microscopy would also
go a long way in the recognition of classic features such as
those seen in Case 2.

Conclusion
The application of the WHO criteria for the diagnosis of
lymphomas including CLL/SLL results in better definition
of disease entities. Where resources allow, morphological
evaluation should be supported by the relevant diagnostic
tests.
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